brentuximab vedotin

brentuximab vedotin


Pharmacologic class: CD30-directed antibody-drug conjugate

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA Box Warning

• John Cunningham virus (JCV) infection resulting in progressive multifocal leukoencephalopathy (PML) and death has been reported in patients treated with brentuximab vedotin.


Brentuximab vedotin antibody is a chimeric IgG1 directed against CD30. The small molecule MMAE is a micro-tubule-disrupting agent. MMAE is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of brentuximab vedotin is due to the binding of the antibody-drug conjugate (ADC) to CD30-expressing cells, followed by internalization of the ADC CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, subsequently inducing cell-cycle arrest and apoptotic death of the cells.


Powder for reconstitution for injection, lyophilized: 50-mg single-use vial

Indications and dosages

Hodgkin's lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who aren't ASCT candidates; systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen

Adults: 1.8 mg/kg I.V. infusion over 30 minutes q 3 weeks; continue treatment until a maximum of 16 cycles, disease progression, or unacceptable toxicity occurs. Calculate dosage for patients weighing more than 100 kg (220 lb) based on a weight of 100 kg.

Dosage adjustment

• Neutropenia

• Peripheral neuropathy


• Concurrent use of bleomycin


Use cautiously in:

• renal or hepatic impairment

• neutropenia, peripheral neuropathy, tumor lysis syndrome, Stevens-Johnson syndrome

• elderly patients (safety and efficacy not established)

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Follow facility policy for handling, preparing, and administering carcinogenic, mutagenic, and teratogenic drugs.

Don't administer by I.V. push or bolus.

Obtain CBC with differential before each dose. Withhold drug for Grade 3 or 4 neutropenia until resolution to baseline or Grade 2 or lower. Be aware that growth factor support should be considered for subsequent cycles in patients who experience Grade 3 or 4 neutropenia. In patients with recurrent Grade 4 neutropenia despite the use of growth factors, consider discontinuation or dosage reduction.

• Reconstitute each 50-mg vial with 10.5 ml sterile water for injection, to yield a single-use solution containing 5 mg/ml. Direct stream toward wall of vial and not directly at powder. Gently swirl vial to aid dissolution. Don't shake.

• Reconstituted solution should be clear to slightly opalescent, colorless, and free of visible particulates.

• Following reconstitution, dilute immediately into infusion bag, or store solution at 2° to 8° C (36° to 46° F) and use within 24 hours of reconstitution. Don't freeze. Discard unused portion.

• Immediately add reconstituted solution to infusion bag containing a minimum volume of 100 ml to achieve a final concentration of 0.4 to 1.8 mg/ml in 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer's injection. Gently invert bag to mix solution. Following dilution, infuse solution immediately, or store solution at 2° to 8° C and use within 24 hours of reconstitution. Don't freeze.

• Don't mix drug with, or administer as an infusion with, other drug products.

Manage neuropathy by using combination of dose delay and dosage reduction as prescribed. For new or worsening Grade 2 or 3 neuropathy, withhold dose until neuropathy improves to Grade 1 or baseline; then restart at dosage prescribed. For Grade 4 peripheral neuropathy, discontinue drug.

If infusion reaction occurs, stop infusion and initiate appropriate medical management. If anaphylaxis occurs, discontinue infusion immediately and initiate appropriate medical management.

If Stevens-Johnson syndrome occurs, discontinue drug and initiate appropriate medical therapy.

Consider the diagnosis of PML in any patient presenting with new-onset signs and symptoms of CNS abnormalities. Evaluation of PML includes, but isn't limited to, consultation with a neurologist, brain MRI, and lumbar puncture or brain biopsy. Withhold drug if PML is suspected; discontinue drug if PML is confirmed.

Adverse reactions

CNS: headache, dizziness, insomnia, anxiety, peripheral sensory neuropathy, peripheral motor neuropathy, fatigue

EENT: oropharyngeal pain

GI: nausea, vomiting, diarrhea, constipation, abdominal pain

Hematologic: neutropenia, anemia, thrombocytopenia

Musculoskeletal: arthralgia, myalgia, back pain, extremity pain, muscle spasms

Respiratory: upper respiratory tract infection, cough, dyspnea

Skin: rash, pruritus, alopecia, dry skin, Stevens-Johnson syndrome

Other: pyrexia, lymphadenopathy, chills, pain, peripheral edema, night sweats, decreased appetite, decreased weight, tumor lysis syndrome, sepsis, infusion reactions and anaphylaxis


Drug-drug. Strong CYP3A4 inducers (such as rifampin): reduced MMAE exposure

Strong CYP3A4 inhibitors (such as ketoconazole): increased MMAE exposure and risk of adverse reactions

Patient monitoring

• Monitor renal and hepatic function tests closely.

• Monitor CBC with differential.

Continue to closely monitor patient for infusion reaction and take appropriate measures.

• Monitor patient for neuropathy and manage appropriately.

Be aware that concurrent use of bleomycin increases risk of pulmonary toxicity. Watch for cough, dyspnea, and other serious respiratory problems, such as interstitial infiltration or inflammation.

Be aware that patients with rapidly proliferating tumor and high tumor burden are at risk for tumor lysis syndrome; closely monitor these patients for hyperphosphatemia, hypocalcemia, hyperuricemia, hyperkalemia, and acute renal failure and take appropriate measures.

Continue to closely monitor neurologic function for signs and symptoms of PML (such as paresis, cognitive impairment, and problems with coordination).

Continue to closely monitor patients for signs and symptoms of Stevens-Johnson syndrome (such as hives, red or purple skin, rash, blisters).

Patient teaching

Instruct patient to immediately contact prescriber if signs and symptoms of infusion reactions (including fever, chills, rash, or breathing problems) occur within 24 hours of infusion.

Instruct patient to immediately contact prescriber if neurologic signs or symptoms of PML occur (such as problems with coordination, decreased strength or weakness, confusion, or problems thinking).

Instruct patient to immediately seek medical attention if hives, red or purple skin, rash, or blisters occur.

• Advise patient to report numbness or tingling of the hands or feet.

• Advise patient to contact prescriber if a fever (temperature of 38° C [100.5° F] or greater) or other evidence of potential infection (such as chills, cough, or pain on urination) develops.

• Counsel female patient of childbearing age to avoid pregnancy and breastfeeding while receiving this drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
References in periodicals archive ?
-Record ADCETRIS[R] (Brentuximab Vedotin) Net Sales in U.S.
(NASDAQ: SGEN) is presenting data from its Adcetris (brentuximab vedotin) clinical development programme at the 24th Annual Congress of the European Hematology Association taking place June 13-16 in Amsterdam; and the International Conference on Malignant Lymphoma from June 18-22 in Lugano, the company said.
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma: 3-year Update of the ECHELON-1 Study: This poster presentation examines progression-free survival outcomes per investigator assessment in the intent-to-treat population of 1,334 patients at three-years by PET status and in patients less than 60 years old.
The Phase 2 KEYNOTE-087 study of pembrolizumab had the following three cohorts: patients which relapsed and/or refractory disease after ASCT and following brentuximab vedotin therapy (Cohort 1); patients who did not respond to chemotherapy, who were ineligible for ASCT, and who had progressive disease after brentuximab vedotin therapy (Cohort 2); and patients with relapsed and/or refractory disease after ASCT, but who had not received post-ASCT treatment as brentuximab vedotin (Cohort 3; ORR 80%) (20).
Also, Wright has experience of cGMP manufacture of 25 ADC projects, including the manufacture of ADCETRIS (brentuximab vedotin), a CD30-targeting ADC for the treatment of relapsed or refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, which was one of the first ADCs approved.
Food and Drug Administration approval of Adcetris (brentuximab vedotin) has been expanded to include adults with untreated stage III or IV classical Hodgkin's lymphoma, the agency said Tuesday in a news release.
In a CheckMate phase II clinical trial, 80 patients with R/R cHL after ASCT and brentuximab vedotin were treated with nivolumab [57].
Takeda has its own track record of oncology product launches, including Adcetris (Brentuximab Vedotin), Ninlaro (ixazomib) and Velcade (bortezomib).
SAN DIEGO -- For patients with CD30-expressing cutaneous T-cell lymphoma, antibody-drug conjugate therapy with brentuximab vedotin significantly outperformed two standard regimens in a phase III trial.
Patel et al., "Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding," Journal of Cutaneous Pathology, vol.